PeerVoice Heart & Lung Video PeerVoice

Visit https://www.peervoice.com/HPP860 to view the entire programme with slides. After completing “Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC”, participants will be able to: Differentiate between pathophysiology of MET alterations in patients with NSCLC and the recommended strategies for their detection; Apply best practices to overcome challenges in the identification of patients with NSCLC and MET vulnerabilities; and Summarize current and emerging strategies for targeting MET alterations as a therapeutic vulnerability in patients with NSCLC.

Visit https://www.peervoice.com/RVW860 to view the entire programme with slides. After completing “Simon Couillard, MD, MSc - Improving Outcomes in Severe Eosinophilic Asthma: Translating Recent Evidence With Biologics Into Patient Care”, participants will be able to: Discuss the pathogenic mechanisms in severe eosinophilic asthma and the role of biomarkers in informing treatment; Describe the role of biologics in improving patient outcomes and their impact on background medication use; and Outline the most recent real-world evidence with biologics for severe eosinophilic asthma and its clinical implications for patient management.

Visit https://www.peervoice.com/QJJ860 to view the entire programme with slides. After completing “Javed Butler, MD, MPH, MBA - Practical Perspectives and Straightforward Strategies for Optimising GDMT in HFrEF: The Role of ARNI as a Fundamental Building Block”, participants will be able to: Explain the role of combination angiotensin receptor neprilysin inhibitor therapy (ARNI) as a component of guideline-directed medical therapy (GDMT) in heart failure (HF); Formulate practical strategies for incorporating renin-angiotensin-aldosterone system (RAAS) inhibition, including ARNI, in management plans for patients with HF; and Apply recommended monitoring and management strategies to optimise the safety and efficacy of RAAS inhibition, including ARNI, in HF.

Visit https://www.peervoice.com/ZFW860 to view the entire programme with slides. After completing “Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care”, participants will be able to: Summarise key data which informs guideline-driven interventions for patients with chronic obstructive pulmonary disease (COPD); Identify treatable traits which can guide need for non-pharmacologic interventions and selection of pharmacotherapy, including triple therapy, for patients with COPD; and Use patient- and disease-specific considerations and treatable traits to guide comprehensive management strategies for patients with COPD.

Visit https://www.peervoice.com/BSG860 to view the entire programme with slides. After completing “George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action”, participants will be able to: Summarise the evidence supporting the need for the current 2024 COVID-19 vaccination campaign for older adults and vulnerable individuals; and Outline the key recommendations by the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC) on the current 2024 COVID-19 vaccination roll-out.

Visit https://www.peervoice.com/GFE860 to view the entire programme with slides. After completing “Geoffrey Liu, MD, MSc, FRCPC, FISPE - Optimizing the Potential for Patients With ALK-Positive mNSCLC Throughout Their Treatment Journey”, participants will be able to: Discuss the importance of first-line treatment and the factors to consider when selecting a treatment strategy for patients with ALK-positive metastatic non–small-cell lung cancer (mNSCLC); Describe the evolving clinical evidence and guideline recommendations for the treatment of ALK-positive mNSCLC; Review the toxicities of the new generation tyrosine kinase inhibitors (TKIs) used as first-line in the treatment of ALK-positive mNSCLC; and Apply key learnings and strategies to enhance the toxicity management of new generation TKIs for optimal patient outcomes.